Repare Therapeutics Inc (RPTX)
3.25
-0.01
(-0.31%)
USD |
NASDAQ |
Nov 14, 16:00
3.24
-0.01
(-0.31%)
After-Hours: 20:00
Repare Therapeutics Net Income (Quarterly): -34.41M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -34.41M |
June 30, 2024 | -34.77M |
March 31, 2024 | 13.16M |
December 31, 2023 | -28.03M |
September 30, 2023 | -18.88M |
June 30, 2023 | -11.95M |
March 31, 2023 | -34.94M |
December 31, 2022 | -31.66M |
September 30, 2022 | 75.46M |
June 30, 2022 | -38.09M |
March 31, 2022 | -34.76M |
December 31, 2021 | -28.29M |
Date | Value |
---|---|
September 30, 2021 | -30.89M |
June 30, 2021 | -26.31M |
March 31, 2021 | -21.42M |
December 31, 2020 | -15.26M |
September 30, 2020 | -13.75M |
June 30, 2020 | -11.80M |
March 31, 2020 | -12.60M |
December 31, 2019 | -8.331M |
September 30, 2019 | -7.688M |
June 30, 2019 | -6.359M |
March 31, 2019 | -4.838M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-38.09M
Minimum
Jun 2022
75.46M
Maximum
Sep 2022
-17.38M
Average
-23.86M
Median
Net Income (Quarterly) Benchmarks
Aurinia Pharmaceuticals Inc | 14.35M |
Edesa Biotech Inc | -1.668M |
Lexaria Bioscience Corp | -1.782M |
InMed Pharmaceuticals Inc | -1.938M |
Xenon Pharmaceuticals Inc | -57.92M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 34.84M |
EPS Diluted (Quarterly) | -0.81 |
Enterprise Value | -41.27M |
Earnings Yield | -61.54% |
Normalized Earnings Yield | -50.45 |